| Catalog No. | HB183016 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Hyaluronate receptor, MDU2, HUTCH-I, MDU3, Phagocytic glycoprotein I, CDw44, Epican, Phagocytic glycoprotein 1, ECMR-III, CD44, Hermes antigen, PGP-1, PGP-I, GP90 lymphocyte homing/adhesion receptor, LHR, CD44 antigen, MIC4, Extracellular matrix receptor III, Heparan sulfate proteoglycan |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P16070 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | BIWA4, 214559-60-1 |
|---|
| Background | Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells. |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
